A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs PF 4958242 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MAD
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Apr 2015.
    • 01 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top